Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.

ABSTRACT: Neoadjuvant chemotherapy is considered a new treatment option for potentially resectable pancreatic cancer. However, data are not well established on overall survival and delaying surgery in resectable pancreatic cancer, as well as on those patients that ultimately cannot undergo surgery. We analyzed pancreatic cancer patients treated in a tertiary hospital from January 2016 to December 2020. Patients with resectable stage I and II pancreatic cancer were evaluated regarding surgery, neoadjuvant treatment, and other clinical demographics. The survival function was estimated using the Kaplan-Meier method, and the relationship between the variables of interest and the overall survival (OS) was assessed by adopting the proportional regression Cox models. A total of 216 patients were evaluated.

SUBMITTER: Uson Junior PLS 

PROVIDER: S-EPMC9365816 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature